No Data
No Data
89Bio Inc. Reports Q3 2024 Financial Results
89bio Announces New Analyses of Data From Phase 2b ENLIVEN Trial
89bio, Inc. Presents New Data From Phase 2b ENLIVEN Trial of Pegozafermin for Advanced MASH at AASLD 2024
89bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the ENLIVEN Phase 2b Trial in MASH Patients at AASLD The Liver Meeting 2024
Express News | 89Bio Presents New Analyses Evaluating Pegozafermin and Potential Benefit of Non-Invasive Tests From the Enliven Phase 2B Trial in Mash Patients at Aasld the Liver Meeting® 2024
89bio (ETNB) Receives a Hold From Oppenheimer